Hisashi Yamanaka

researcher

Hisashi Yamanaka is …
instance of (P31):
humanQ5

External links are
P496ORCID iD0000-0001-8453-6731

P108employerInternational University of Health and WelfareQ11422387
Tokyo Women's Medical UniversityQ11524729
P106occupationresearcherQ1650915

Reverse relations

author (P50)
Q39288606A Case of Human Leukocyte Antigen (HLA) B27-Positive Intestinal Behçet's Disease with Crohn's Disease-Like Anal Fistulas
Q91944393A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis
Q33765587A GC polymorphism associated with serum 25-hydroxyvitamin D level is a risk factor for hip fracture in Japanese patients with rheumatoid arthritis: 10-year follow-up of the Institute of Rheumatology, Rheumatoid Arthritis cohort study
Q54128836A case of enteropathic arthritis successfully treated with methotrexate.
Q92852261A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week)
Q34439062A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout
Q38082506A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria
Q28943458A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese
Q93053452A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today's treatment options
Q57918301A large-scale association study identified multiple HLA-DRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects
Q30565447A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study
Q40923160A novel peptide from TCTA protein inhibits proliferation of fibroblast-like synoviocytes of rheumatoid arthritis patients
Q84190342A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility
Q40504910A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy
Q79368451A role for TARC/CCL17, a CC chemokine, in systemic lupus erythematosus
Q90582516A simple screening test to assess risk of falls in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study
Q41002699A twin study of rheumatoid arthritis in the Japanese population
Q46235038A1330V polymorphism of low-density lipoprotein receptor-related protein 5 gene and self-reported incident fractures in Japanese female patients with rheumatoid arthritis
Q34335866ACPA-negative RA consists of two genetically distinct subsets based on RF positivity in Japanese
Q31054046Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study
Q42484856Activation of the activin A-ALK-Smad pathway in systemic sclerosis
Q36603276Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.
Q34118958Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
Q40569751Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.
Q92211637Age and female gender associated with periodontal disease in Japanese patients with rheumatoid arthritis: Results from self-reported questionnaires from the IORRA cohort study
Q84305974An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan
Q84305957An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Ja
Q41126608An association between amino acid position 74 of HLA-DRB1 and anti-citrullinated protein antibody levels in Japanese patients with anti-citrullinated protein antibody-positive rheumatoid arthritis
Q34020575An osteoprotegerin gene polymorphism is associated with an increased risk of hip fracture in Japanese patients with rheumatoid arthritis: results from the IORRA Observational Cohort Study
Q45190511Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA.
Q72025720Analysis of the Genotypes for Aldehyde Dehydrogenase 2 in Japanese Patients with Primary Gout
Q51038707Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients.
Q84141907Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
Q83135225Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus
Q38650673Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis
Q35605019Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population
Q51155261Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan.
Q64101585Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: contribution to the novel treatment
Q85210559Arterial Calcification Due to Deficiency of CD73 (ACDC) As One of Rheumatic Diseases Associated With Periarticular Calcification
Q53654897Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice.
Q50737007Associated factors for falls and fear of falling in Japanese patients with rheumatoid arthritis.
Q28275244Association between PADI4 and rheumatoid arthritis: a replication study
Q33929673Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: a case-control study
Q86648791Association between serum vitamin D level and history of falls in elderly Japanese patients with rheumatoid arthritis
Q82897566Association of EMCN with susceptibility to rheumatoid arthritis in a Japanese population
Q47965620Association of Takayasu arteritis with HLA-B 67:01 and two amino acids in HLA-B protein
Q64109926Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for and CD39
Q36980377Association-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritis
Q46068058Associations between methotrexate treatment and methylenetetrahydrofolate reductase gene polymorphisms with incident fractures in Japanese female rheumatoid arthritis patients
Q51756404Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort.
Q35214632Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.
Q51629157Bone erosion of the sternocostal joint in a patient with Behcet's disease.
Q44079603Brief Report: Main Contribution of DRB1*04:05 Among the Shared Epitope Alleles and Involvement of DRB1 Amino Acid Position 57 in Association With Joint Destruction in Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis
Q54491385Brief report: Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population.
Q53715028Capillary abnormalities observed by nailfold video-capillaroscopy in Japanese patients with systemic sclerosis.
Q79402016Cartilage oligomeric matrix protein in serum and synovial fluid of rheumatoid arthritis: potential use as a marker for joint cartilage damage
Q38401295Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort
Q81892214Chondrocyte of rheumatoid arthritis serve as a source of intra-articular acute-phase serum amyloid A protein
Q50591145Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
Q53244092Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study.
Q40353155Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
Q40948951Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results
Q50010475Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.
Q82900763Clinical images: Dramatic amelioration of pneumatosis cystoides intestinalis in systemic sclerosis
Q85004068Clinical images: Solitary extranodal malignant lymphoma of the forearm in rheumatoid arthritis
Q43055408Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis
Q40361295Clinical manifestations of neurological involvement in primary Sjögren’s syndrome
Q35223223Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study
Q44187213Comorbidities in patients with gout
Q35760044Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values
Q37398907Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
Q43880563Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute
Q77930175Comparison of the Rau method and the Larsen method in the evaluation of radiographic progression in early rheumatoid arthritis
Q82397612Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis
Q87451118Construct validity, reliability, response rate, and association with disease activity of the quick disabilities of the arm, shoulder and hand questionnaire in the assessment of rheumatoid arthritis
Q39138031Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with Rheumatoid Arthritis
Q58204803Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study
Q37153054Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis
Q30882161Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study
Q33628713Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus
Q46341530DMARDs (disease-modifying antirheumatic drugs)
Q39636360Dental treatments, tooth extractions, and osteonecrosis of the jaw in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study
Q38817265Design characteristics of the Corrona Japan rheumatoid arthritis registry
Q51354997Detection of IFN-γ+IL-17+ cells in salivary glands of patients with Sjögren's syndrome and Mikulicz's disease: Potential role of Th17•Th1 in the pathogenesis of autoimmune diseases.
Q40492098Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises
Q89775823Diagnostic Rate of Autoinflammatory Diseases Evaluated by Fever Patterns in Pediatric- and Adult-Onset Patients
Q33526071Diagnostic reliability of magnetic resonance imaging for central nervous system syndromes in systemic lupus erythematosus: a prospective cohort study
Q71077133Dihydroxyadenine Urolithiasis in Children with Partial Deficiency of Adenine Phosphoribosyltransferase
Q83970283Disability and patient's appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan
Q43752980Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab
Q58204763Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity
Q40859479Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study
Q34654491Discoveries in the pathophysiology of neuropsychiatric lupus erythematosus: consequences for therapy
Q58204670Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies
Q55311957Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody.
Q72025527Effect of Hypouricemic Agents on Serum Carbohydrate-Deficient Transferrin in Gouty Patients
Q27335031Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).
Q50450005Effect of Smoking on Remission Proportions Differs Between Male and Female Patients with Rheumatoid Arthritis: A Study Based on the IORRA Survey.
Q24658507Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate
Q43589081Effect of genetic polymorphisms on development of gout
Q45900492Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Q54571820Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy.
Q43057629Effect of total knee arthroplasty on disease activity in patients with established rheumatoid arthritis: 3-year follow-up results of combined medical therapy and surgical intervention
Q34012929Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).
Q90228096Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan
Q39603215Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
Q44046983Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan
Q87400701Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis
Q91571694Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan
Q86707957Effects of febuxostat on serum urate level in Japanese hyperuricemia patients
Q42667045Effects of smoking and shared epitope on the production of anti-citrullinated peptide antibody in a Japanese adult population
Q91622660Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled
Q58204675Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia®as Biological Intensive Treatment for RA (ORBIT) study
Q46030948Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
Q54268275Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
Q83219587Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up
Q53789625Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial.
Q52658631Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).
Q47656412Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study.
Q43019736Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis
Q92793763Efficacy and safety of tacrolimus in patients with rheumatoid arthritis - A systematic review and meta-analysis
Q36761766Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
Q92546940Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data
Q93389625Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data
Q34768442Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).
Q50911722Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate.
Q64280212Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study
Q83528740Efficacy of total joint arthroplasty in patients with established rheumatoid arthritis: improved longitudinal effects on disease activity but not on health-related quality of life
Q79429257Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA
Q36792701Elevated Ratio of Th17 Cell-Derived Th1 Cells (CD161(+)Th1 Cells) to CD161(+)Th17 Cells in Peripheral Blood of Early-Onset Rheumatoid Arthritis Patients
Q51733238Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA.
Q90788552Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey
Q50026281Erratum to: Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity
Q58204768Erratum to: Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity
Q42205699Erythematosus plaques with macrophage infiltration as an initial manifestation of macrophage activation syndrome in a patient with systemic lupus erythematosus
Q30699182Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I).
Q36519316Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.
Q54769767Expression and function of the co-stimulator H4/ICOS on activated T cells of patients with rheumatoid arthritis.
Q47753851Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren's syndrome
Q88810766Factors associated with decreasing serum 25(OH)D among Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study
Q92764697Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
Q80237616Failure to confirm association between PDCD1 polymorphisms and rheumatoid arthritis in a Japanese population
Q81162464Failure to confirm association between SLC22A4 polymorphism and rheumatoid arthritis in a Japanese population
Q44846281Familial juvenile hyperuricemic nephropathy: detection of mutations in the uromodulin gene in five Japanese families
Q58762147Features of patients with rheumatoid arthritis whose debut joint is a foot or ankle joint: A 5,479-case study from the IORRA cohort
Q51040537Fracture risk assessment and osteoporosis treatment disparities in 3,970 Japanese patients with rheumatoid arthritis.
Q53141758Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures.
Q45953331Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study.
Q28943519Functional variants in NFKBIE and RTKN2 involved in activation of the NF-κB pathway are associated with rheumatoid arthritis in Japanese
Q56892305Genetic differences between type 1 diabetes with and without other autoimmune diseases
Q47660508Genetic landscape of interactive effects of HLA-DRB1 alleles on susceptibility to ACPA(+) rheumatoid arthritis and ACPA levels in Japanese population.
Q29417000Genetics of rheumatoid arthritis contributes to biology and drug discovery
Q28489093Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis
Q45969381Geranylgeranylacetone, a non-toxic inducer of heat shock protein, induces cell death in fibroblast-like synoviocytes from patients with rheumatoid arthritis.
Q45129676Ghrelin attenuates collagen production in lesional fibroblasts from patients with systemic sclerosis
Q36023494Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
Q37130039Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through
Q90000728Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout
Q50107620HLA-DRB1 Analysis Identified a Genetically Unique Subset within Rheumatoid Arthritis and Distinct Genetic Background of Rheumatoid Factor Levels from Anticyclic Citrullinated Peptide Antibodies
Q39762134High frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis
Q84819866Human osteoclastogenic T cells and human osteoclastology
Q83504239Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM
Q40467474Hypersensitivity reaction against influenza vaccine in a patient with rheumatoid arthritis after the initiation of etanercept injections.
Q49986881Hypouricaemic effects of yogurt containing Lactobacillus gasseri PA-3 in patients with hyperuricaemia and/or gout: a randomized, double-blind, placebo-controlled study
Q41674783IL-23 and Th17 Disease in Inflammatory Arthritis
Q91091035IL-35 inhibits human osteoclastogenesis from monocytes induced by receptor-activator of NF-κB ligand
Q42017411ITGAV polymorphism and disease susceptibility in a Japanese rheumatoid arthritis population
Q33865598Identification of three new autoantibodies associated with systemic lupus erythematosus using two proteomic approaches
Q28295686Identification of two novel mutations in adenine phosphoribosyltransferase gene in patients with 2,8-dihydroxyadenine urolithiasis
Q98175816Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
Q31024819Impact of shoulder, elbow, and knee joint involvement on assessment of rheumatoid arthritis using the American College of Rheumatology Core Data Set.
Q80786293Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan
Q51778965Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA.
Q40061090Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis
Q50668086Incidence of falls and fear of falling in Japanese patients with rheumatoid arthritis.
Q39043571Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010.
Q84232701Incidence of malignancy in Japanese patients with rheumatoid arthritis
Q51022571Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab.
Q84483237Increased HGF and c-Met in muscle tissues of polymyositis and dermatomyositis patients: beneficial roles of HGF in muscle regeneration
Q84045856Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis
Q80164912Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IOR
Q43205833Inhibition of NF-kappaB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis
Q58587095Integration of genetics and miRNA-target gene network identified disease biology implicated in tissue specificity
Q84219583Interferon-induced helicase (IFIH1) polymorphism with systemic lupus erythematosus and dermatomyositis/polymyositis
Q42986598Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease
Q83172955Interleukin-18 promoter polymorphisms in Japanese patients with rheumatoid arthritis: protective effect of the T allele and T/T genotype at rs360722
Q54541525Lack of association between IL-15 genetic variants and progression of joint destruction in Japanese patients with rheumatoid arthritis.
Q46411939Leflunomide for therapy of rheumatoid arthritis
Q46387828Leflunomide: clinical effectiveness and mechanism of action
Q48106958Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study
Q36761836Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
Q50539598Longer operative time is the risk for delayed wound healing after forefoot surgery in patients with rheumatoid arthritis.
Q37697988Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
Q42871560MHC2TA is associated with rheumatoid arthritis in Japanese patients
Q48676933Major depressive disorder in patients with rheumatoid arthritis
Q38024661Management of rheumatoid arthritis: the 2012 perspective
Q28943303Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population
Q37228791Molecular aspects of rheumatoid arthritis: role of transcription factors
Q34778142Molecular targets of rheumatoid arthritis
Q84305978Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout
Q82254358Multiple extensor tendon ruptures caused by tophaceous gout
Q82106901NR2-reactive antibody decreases cell viability through augmentation of Ca(2+) influx in systemic lupus erythematosus
Q50607119Neurocognitive impairment in corticosteroid-naive patients with active systemic lupus erythematosus: a prospective study.
Q48229388New-onset psychiatric disorders after corticosteroid therapy in systemic lupus erythematosus: an observational case-series study
Q44553220No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan
Q93209255Non-increased risk of thrombosis by steroid pulse therapy in patients with lupus nephritis from the Japanese health insurance database
Q83477053Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility in Japanese rheumatoid arthritis patients
Q80469281Nonsteroidal anti-inflammatory drug use does not affect short-term endoscopic and histologic outcomes after Helicobacter pylori eradication in patients with rheumatoid arthritis
Q51073334Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan.
Q51773719One third of Japanese patients with rheumatoid arthritis use complementary and alternative medicine.
Q82543436Opinions of Japanese rheumatology physicians regarding clinical practice guidelines
Q34664095PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study
Q85355710PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population
Q85233288Performance of hands and feet radiographs in differentiation of psoriatic arthritis from rheumatoid arthritis
Q31118397Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan
Q44268290Pharmacogenetics of disease modifying anti-rheumatic drugs
Q88790397Pharmacogenomics in the treatment of rheumatoid arthritis: clinical implication and perspective
Q84305970Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study
Q84305962Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study
Q38758623Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis
Q43943522Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses
Q98565632Polypharmacy, declined walking speed, bent back, and disability associated with a history of falls in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study
Q36981521Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis
Q35154359Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
Q36981540Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
Q38382764Postmarketing surveillance of the safety and effectiveness of etanercept in Japan
Q35540000Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
Q36457940Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice
Q92150538Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study
Q91886454Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies
Q48069664Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis
Q44459400Prevalence of Helicobacter pylori infection and risk of upper gastrointestinal ulcer in patients with rheumatoid arthritis in Japan
Q45352834Prevalence of and factors associated with vitamin D deficiency in 4,793 Japanese patients with rheumatoid arthritis
Q46969832Prevalence of polymorphisms of the genes responsible for auto-inflammatory diseases among 202 patients with recurrent fever in a rheumatology institute in Japan
Q58204586Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study
Q56957893Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
Q54369842Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three: Genoa, Italy. 28 September – 01 October 2016.
Q47784999Productivity loss of Japanese patients with rheumatoid arthritis - A cross-sectional survey
Q40860110Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; Analysis of the IORRA database
Q83204055Quantitative effect of HLA-DRB1 alleles to ACPA levels in Japanese rheumatoid arthritis: no strong genetic impact of shared epitope to ACPA levels after stratification of HLA-DRB1*09:01
Q41618762RANK Expression and Osteoclastogenesis in Human Monocytes in Peripheral Blood from Rheumatoid Arthritis Patients.
Q50207113RANKL: A therapeutic target for bone destruction in rheumatoid arthritis
Q43285118Radiographic repair in three Japanese patients with rheumatoid arthritis treated with bucillamine
Q82771356Rapid progressive cerebral atrophy in systemic lupus erythematosus
Q36936735Ratio of Circulating IFNγ (+) "Th17 Cells" in Memory Th Cells Is Inversely Correlated with the Titer of Anti-CCP Antibodies in Early-Onset Rheumatoid Arthritis Patients Based on Flow Cytometry Methods of the Human Immunology Project
Q96582855Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data
Q42363118Rebamipide, an Amino Acid Analog of 2(1H)-Quinolinone, Inhibits the Formation of Human Osteoclasts
Q30791566Recent trends in orthopedic surgery aiming to improve quality of life for those with rheumatoid arthritis: data from a large observational cohort
Q37706297Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
Q47276595Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort
Q70200627Relationship between phosphorylation and cytotoxicity of 2-chloroadenosine and 6-methylmercaptopurine riboside in human cells
Q83404830Reparative radiological changes of a large joint after adalimumab for rheumatoid arthritis
Q42843728Response to 'Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study'.
Q46559560Response to: 'Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossini et al.
Q58204917Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM)
Q58204927Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM)
Q36517701Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
Q44650673Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J).
Q85736797Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis
Q51774665Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study.
Q44160522Risk factors associated with incident fractures in Japanese men with rheumatoid arthritis: a prospective observational cohort study
Q51187397Risk factors associated with the occurrence of distal radius fractures in Japanese patients with rheumatoid arthritis: a prospective observational cohort study.
Q50929858Risk factors associated with the occurrence of proximal humerus fractures in patients with rheumatoid arthritis: a custom strategy for preventing proximal humerus fractures.
Q43432276Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: Results from a large prospective observational cohort study
Q81329527Risk factors for wrist surgery in rheumatoid arthritis
Q83343362Risperidone in the treatment of corticosteroid-induced mood disorders, manic/mixed episodes, in systemic lupus erythematosus: a case series
Q46120324Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs
Q57788201Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance
Q45098990Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients
Q58204787Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients
Q35999197Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study
Q35999139Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
Q39430200Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab.
Q72025577Search for the Mechanisms of High Incidence of APRT Deficiency Among Japanese
Q83065546Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases
Q55055892Serum antibodies against the 70k polypeptides of the U1 ribonucleoprotein complex are associated with psychiatric syndromes in systemic lupus erythematosus: a retrospective study.
Q54635163Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis.
Q92708671Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor
Q84146461Single nucleotide polymorphisms of CD244 gene predispose to renal and neuropsychiatric manifestations with systemic lupus erythematosus
Q55417294Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.
Q39445978Sites, frequencies, and causes of self-reported fractures in 9,720 rheumatoid arthritis patients: a large prospective observational cohort study in Japan
Q44960769Spinal tophaceous gout mimicking a spinal tumor.
Q83943709Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006
Q47658083Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study
Q58204792Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept
Q35610255Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database
Q51664446Successful delivery in a patient with clinically amyopathic dermatomyositis during pregnancy despite first-trimester acute exacerbation of interstitial lung disease.
Q46186828Successful treatment for sympathetic storms in a patient with neuro-Behçet's disease
Q89212644Survey of attitudes of non-pediatric rheumatologists among councilors of the Japan College of Rheumatology regarding transitional care
Q37320282Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
Q30981893T-cell leukemia translocation-associated gene (TCTA) protein is required for human osteoclastogenesis
Q84115953Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation
Q51245055Technetium-99m Albumin Scintigraphy in Protein-Losing Gastroenteropathy With Systemic Lupus Erythematosus: Typical Diagnostic Pattern of Radiotracer Leakage and Chronological Improvement by Treatment.
Q42647387The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population
Q92388080The evaluation of gene polymorphisms associated with autoinflammatory syndrome in patients with palindromic rheumatism complicated by intermittent hydrarthrosis
Q36475622The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression
Q84903753The increasing disease duration of patients at the time of orthopaedic surgery for rheumatoid arthritis
Q44137407The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis
Q83249220The influence of individual joint impairment on functional disability in rheumatoid arthritis using a large observational database of Japanese patients
Q46349860The influence of sex on patients with rheumatoid arthritis in a large observational cohort
Q84337249The intra-articular efficacy of hyaluronate injections in the treatment of rheumatoid arthritis
Q88600926The minimally important difference for the Japanese version of the health assessment questionnaire in patients with rheumatoid arthritis in daily practice
Q45388766Therapeutic effects of alendronate on bone erosion and atrophy in a patient with rheumatoid arthritis and hepatitis C virus infection
Q79211749Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study
Q90853719Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan: Results of long-term postmarketing surveillance
Q88937944Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the S
Q36513512Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
Q40115649Tonsillectomy to Effectively Treat a Patient with Behçet's Disease
Q41610320Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan
Q51309543Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Q84435770Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5*01:05 allele in scleroderma patients with interstitial lung disease
Q92811599Updated version of Japanese Childhood Health Assessment Questionnaire (CHAQ)
Q45944691Urinary free light chain is a potential biomarker for ISN/RPS class III/IV lupus nephritis.
Q47364378Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis
Q80337026Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice
Q33540305Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study
Q83382040[ Bone and cartilage destruction in RA and its intervention. Disease-modifying antirheumatic drugs]
Q85353653[A case of Sjögren syndrome suspected, rheumatoid arthritis and Behcet's disease complicated with cochlear nerve and trigeminal nerve disorders]
Q73107916[Basic calcium phosphate crystal deposition disease]
Q81593772[Immunological and serological tests for diagnosis of rheumatoid arthritis: MMP-3]
Q80644978[Maintenance therapy for rheumatoid arthritis after remission following successful treatment using biologics]
Q80413911[Prospective cohort studies of incident fractures in patients with rheumatoid arthritis]
Q73107914[Pseudogout--calcium pyrophosphate dihydrate crystal deposition disease]
Q95370616[Rheumatic diseases and sex differences]
Q94853673[Serum markers of synovitis and bone metabolism in rheumatoid arthritis]

Search more.